The decrease of dopamine D 2/D 3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB 1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D 2/D 3 antagonist [ 3H]raclopride and the novel CB 1 inverse agonis

Brain Research Bulletin

Volumn 87, Issue 6, 2012, Pages 504-510

  Farkas, Szabolcs ^a   Nagy, Katalin ^a   Jia, Zhisheng ^b   Harkany, Tibor ^b   Palkovits, Miklós ^c   Donohou, Sean R ^d   Pike, Victor W ^d   Halldin, Christer ^b   Máthé, Domokos ^e,f   Csiba, László ^a   Gulyás, Balázs ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f CROmed Ltd   (Hungary)

Author keywords

Dopamine D 2 D 3 receptor; Endocannabinoid CB1 receptor; Human brain autoradiography; Molecular imaging biomarker; Parkinson's disease; Striatum

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LEVODOPA; RACLOPRIDE; RADIOLIGAND; SD 7015 I 125; UNCLASSIFIED DRUG;

ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; HUMAN; HUMAN TISSUE; MIDDLE FRONTAL GYRUS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SAMPLE SIZE;

AGED; AUTORADIOGRAPHY; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; PARKINSON DISEASE; PROTEIN BINDING; PUTAMEN; PYRAZOLES; RACLOPRIDE; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; THIRAM;

EID: 84859155879     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.02.012     Document Type: Article

References (106)

1. Alexander G.M., Schwartzman R.J., Grothusen J.R., Brainard L., Gordon S.W. Change in brain dopamine receptor in MPTP parkinsonian monkeys following L-DOPA treatment. Brain Res. 1993, 625:276-282.
2. 2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res. 1995, 691:106-114.
3. 11C]raclopride. Mov. Disord. 1997, 12:33-38.
4. 2 short receptors and induces receptor sequestration. J. Neural Transm. 1997, 104:867-874.
5. 125I] labeled ligands with Amersham Hyperfilm β-max. Neurosci. Lett. 1989, 104:171-177.
6. Blanchard V., Chritin M., Vyas S., Savasta M., Feuerstein C., Agid Y., Javoy-Agid F., Raisman-Vozari R. Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J. Neurochem. 1995, 64:1669-1679.
7. 2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 1995, 272:854-859.
8. Blázquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., Palazuelos J., Julien B., Salazar M., Börner C., Benito C., Carrasco C., Diez-Zaera M., Paoletti P., Díaz-Hernández M., Ruiz C., Sendtner M., Lucas J.J., de Yébenes J.G., Marsicano G., Monory K., Lutz B., Romero J., Alberch J., Ginés S., Kraus J., Fernández-Ruiz J., Galve-Roperh I., Guzmán M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011, 134:119-136.
9. 1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 1995, 270:13973-13980.
10. 1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 2003, 3:54-61.
11. Cai G., Wang H.Y., Friedman E. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J. Pharmacol. Exp. Ther. 2002, 302:1105-1112.
12. 1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn. Mem. 2004, 11:625-632.
13. Carrier E.J., Auchampach J.A., Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. USA 2006, 103:7895-7900.
14. 2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys. Neuropsychopharmacology 2008, 33:270-278.
15. Chen J., Paredes W., Li J., Smith D., Lowinson J., Gardner E.L.Δ9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psycopharmacology 1990, 102:156-162.
16. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 1998, 5:534-551.
17. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
18. Di Filippo M., Picconi B., Tozzi A., Ghiglieri V., Rossi A., Calabresi P. The endocannabinoid system in Parkinson's disease. Curr. Pharm. Des. 2008, 14:2337-2347.
19. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 2000, 14:1432-1438.
20. 1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 2000, 75:2434-2444.
21. S.R. Donohue, Development of Cannabinoid Subtype-1 (CB1) Receptor Ligands for PET, Karolinska Institutet, PhD Thesis (2008).
22. Donohue S.R., Varnäs K., Jia Z., Gulyás B., Pike V.W., Halldin C. Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors. Bioorg. Med. Chem. Lett. 2009, 19:6209-6212.
23. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
24. 2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal mesencephalon: an autoradiographic study. Brain Res. 1998, 795:55-62.
25. S. Farkas, K. Nagy, Z. Jia, T. Hortobágyi, A. Varrone, C. Halldin, B. Gulyás, L. Csiba, Signal transduction pathway activity compensates dopamine D2/D3 receptor density changes in Parkinson's disease. Brain Res. (in press).
26. Ferrer B., Asbrock N., Kathuria S., Piomelli D., Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur. J. Neurosci. 2003, 18:1607-1614.
27. Finkelstein D.I., Stanic D., Parish C.L., Tomas D., Dickson K., Horne M.K. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000, 97:99-112.
28. French E.D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997, 8:649-652.
29. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
30. 1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. J. Neural Transm. Suppl. 2009, 73:269-275.
31. Gardner E.L., Vorel S.R. Cannabinoid transmission and reward-related events. Neurobiol. Dis. 1998, 5:502-533.
32. 1 receptors. Eur. J. Pharmacol. 1998, 341:39-44.
33. Giuffrida A., Parsons L.H., Kerr T.M., Rodríguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 1999, 2:358-363.
34. 1 receptor. J. Neurosci. 1997, 17:5327-5333.
35. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
36. Glass M., Dragunow M., Faull R.L.M. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
37. 1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res. 2006, 1073-1074:209-219.
38. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agrò A., Maccarrone M. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 2002, 22:6900-6907.
39. Hall H., Farde L., Sedvall G. Human dopamine receptor subtypes-in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride. J. Neural Transm. 1988, 73:7-21.
40. 3-dopamine receptor agonist (+)-[3H]PD. Psychopharmacology (Berl) 1996, 128:240-247.
41. Hall H., Halldin C., Farde L., Sedvall G. Whole hemisphere autoradiography of the postmortem human brain. Nucl. Med. Biol. 1998, 25:715-719.
42. Hall H., Farde L., Halldin C., Lundkvist C., Sedvall G. Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse 2000, 38:421-431.
43. Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 1998, 95:8268-8273.
44. Hashimotodani Y., Ohno-Shosaku T., Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007, 13:127-137.
45. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 1991, 11:563-583.
46. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 1995, 35:607-634.
47. Hu W., Zhang M., Czéh B., Zhang W., Flügge G. Chronic restraint stress impairs endocannabinoid mediated suppression of GABAergic signaling in the hippocampus of adult male rats. Brain Res. Bull. 2011, 85:374-379.
48. Hudson B.D., Hébert T.E., Kelly M.E. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol. Pharmacol. 2010, 77:1-9.
49. 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural Transm. 2003, 110:1279-1288.
50. Julian M.D., Martin A.B., Cuellar B., Rodriguez De Fonseca F., Navarro M., Moratalla R., Garcia-Segura L.M. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 2003, 119:309-318.
51. 2 receptor partial agonists: treatment of CNS disorders of dopamine function. Curr. Top. Med. Chem. 2008, 8:1068-1888.
52. Kelly C.M., Dunnett S.B., Rosser A.E. Medium spiny neurons for transplantation in Huntington's disease. Biochem. Soc. Trans. 2009, 37:323-328.
53. Kelsey J.E., Harris O., Cassin J. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav. Brain Res. 2009, 203:304-307.
54. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005, 5:400-411.
55. Klein T.W., Friedman H., Specter S.C. Marijuana, immunity and infection. J. Neuroimmunol. 1998, 83:102-115.
56. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., Friedman H. The cannabinoid system and immune modulation. J. Leukoc. Biol. 2003, 74:486-496.
57. Köfalvi A., Rodrigues R.J., Ledent C., Mackie K., Vizi E.S., Cunha R.A., Sperlágh B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J. Neurosci. 2005, 25:2874-2884.
58. Köhler C., Hall H., Ogren S.O., Gawell L. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem. Pharmacol. 1985, 34:2251-2259.
59. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
60. 3 dopamine receptor selective compounds on L-DOPA-dependent abnormal involuntary movements in rats. Neuropharmacology 2009, 56:956-969.
61. Lambert D.M., Fowler C.J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 2005, 48:5059-5087.
62. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's disease and MPTP-treated marmosets. Eur. J. Neurosci. 2001, 14:1827-1832.
63. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 2005, 19:96-107.
64. Lee C.S., Samii A., Sossi V. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
65. Lin Q.S., Yang Q., Liu D.D., Sun Z., Dang H., Liang J., Wang Y.X., Chen J., Li S.T. Hippocampal endocannabinoids play an important role in induction of long-term potentiation and regulation of contextual fear memory formation. Brain Res. Bull. 2011, 86:139-145.
66. 2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. Clin. Neuropharmacol. 1999, 22:277-280.
67. Maccarrone M., Gubellini P., Bari M., Picconi B., Battista N., Centonze D., Bernardi G., Finazzi-Agro A., Calabresi P. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 2003, 85:1018-1025.
68. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sci. 2005, 77:1667-1673.
69. Mailleux P., Vanderhaeghen J.J. Distribution of the neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992, 48:655-688.
70. Maneuf Y.P., Nash J.E., Croosman A.R., Brotchie J.M. Activation of the cannabinoid receptor by D9-THC reduces GABA uptake in the globus pallidus. Eur. J. Pharmacol. 1996, 308:161-164.
71. 2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 1997, 148:265-270.
72. Mechoulam R., Spatz M., Shohami E. Endocannabinoids and neuroprotection. Sci. STKE 2002, 129:RE5.
73. 1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 2001, 40:918-926.
74. Micale V., Mazzola C., Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol. Res. 2007, 56:382-392.
75. 2/3 receptors in rat brain: a quantitative autoradiographic study. Neurochem. Int. 2010, 56:747-752.
76. Molina-Holgado E., Vela J.M., Arévalo-Martín A., Almazán G., Molina-Holgado F., Borrell J., Guaza C. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatylinositol-3 kinase/Akt signaling. J. Neurosci. 2002, 22:9742-9753.
77. Mulder J., Zilberter M., Pasquaré S.J., Alpár A., Schulte G., Ferreira S.G., Köfalvi A., Martín-Moreno A.M., Keimpema E., Tanila H., Watanabe M., Mackie K., Hortobágyi T., de Ceballos M.L., Harkany T. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 2011, 134:1041-1060.
78. Ong W.Y., Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience. 1999, 92:1177-1191.
79. Orgado J.M., Fernández-Ruiz J., Romero J. The endocannabinoid system in neuropathological states. Int. Rev. Psychiatry 2009, 21:172-180.
80. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58:389-462.
81. Pazos M.R., Sagredo O., Fernández-Ruiz J. The endocannabinoid system in Huntington's disease. Curr. Pharm. Des. 2008, 14:2317-2325.
82. Pisani A., Fezza F., Galati S., Battista N., Napolitano S., Finazzi-Agrò A., Bernardi G., Brusa L., Pierantozzi M., Stanzione P., Maccarrone M. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 2005, 57:777-779.
83. Pisani V., Madeo G., Tassone A., Sciamanna G., Maccarrone M., Stanzione P., Pisani A. Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov. Disord. 2011, 26:216-222.
84. Reches A., Wagner H.R., Jackson-Lewis V., Yablonskaya-Alter E., Fahn S. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology 1984, 34:1208-1212.
85. 11C]raclopride. J. Neurol. Sci. 1995, 132:156-161.
86. Romero J., García L., Cebeira M., Zadrozny D., Fernández-Ruiz J.J., Ramos J.A. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci. 1995, 56:2033-2040.
87. Romero J., de Miguel R., Ramos J.A., Fernandez-Ruiz J.J. The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake. Life Sci. 1998, 62:351-363.
88. 1 receptor mRNA levels in the caudate-putamen. Life Sci. 2000, 66:485-494.
89. Rossi S., Bernardi G., Centonze D. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp. Neurol. 2010, 224:92-102.
90. Sánchez C., Galve-Roperh I., Canova C., Brachet P., Guzman M. Δ9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 1998, 436:6-10.
91. Sañudo-Peña M.C., Patrick S.L., Khen S., Patrick R.L., Tsou K., Walker J.M. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett. 1998, 248:171-174.
92. Seeman P., Niznik H.B. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 1990, 4:2737-2744.
93. 2 High states, implying many paths to psychosis. Proc. Natl. Acad. Sci. USA 2005, 102:3513-3518.
94. 1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 2001, 169:400-406.
95. Sossi V., Dinelle K., Topping G.J., Holden J.E., Doudet D., Schulzer M., Ruth T.J., Stoessl A.J., de la Fuente-Fernandez R. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J. Neurochem. 2009, 109:85-92.
96. Szabo B., Müller T., Koch H. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J. Neurochem. 1999, 73:1084-1089.
97. Thobois S., Vingerhoets F., Fraix V., Xie-Brustolin J., Mollion H., Costes N., Mertens P., Benabid A.L., Pollak P., Broussolle E. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch. Neurol. 2004, 61:1705-1709.
98. Valjent E., Pages C., Rogard M., Besson M.J., Maldonado R., Caboche J. Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur. J. Neurosci. 2001, 14:342-352.
99. Waksman Y., Olson J., Carlisle S.J., Cabral G.A. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther. 1999, 288:1357-1366.
100. 1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Res. Bull. 2010, 81:543-548.
101. Walter L., Stella N. Cannabinoids and neuroinflammation. Br. J. Pharmacol. 2004, 141:775-785.
102. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 2003, 23:1398-1405.
103. Wictorin K. Anatomy and connectivity of intrastriatal striatal transplants. Prog. Neurobiol. 1992, 38:611-639.
104. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
105. 2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. PNAS 2006, 103:8251-8256.
106. 1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 1999, 276:71-74.